101. L1 Cell Adhesion Molecule Confers Radioresistance to Ovarian Cancer and Defines a New Cancer Stem Cell Population
- Author
-
Jürgen Grünberg, Roger Schibli, Yen-Lin Huang, Viola Heinzelmann-Schwarz, Claudia Peitzsch, Christiane Krudewig, Francis Jacob, Nastassja Terraneo, Anna Dubrovska, Martin Béhé, University of Zurich, and Grünberg, Jürgen
- Subjects
0301 basic medicine ,Cancer Research ,to ,10184 Institute of Veterinary Pathology ,epithelial ,Biology ,lcsh:RC254-282 ,Article ,03 medical and health sciences ,0302 clinical medicine ,Cancer stem cell ,stem cells ,Radioresistance ,medicine ,1306 Cancer Research ,Clonogenic assay ,Cas9 ,L1 cell adhesion molecule ,ovarian cancer ,radioresistance ,CRISPR-Cas9 ,epithelial-to-mesenchymal transition ,Cancer ,Cell sorting ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,mesenchymal transition ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,CRISPR ,Cancer cell ,Cancer research ,570 Life sciences ,biology ,2730 Oncology ,Stem cell ,Ovarian cancer - Abstract
Many solid tumors, including ovarian cancer, contain small populations of cancer stem cells (CSCs). These cells are usually resistant against conventional cancer therapies and play a role in disease recurrence. We demonstrated that the L1 cell adhesion molecule (L1CAM) is a new CSC target in ovarian cancer, triggering radioresistance. Using fluorescence-activated cell sorting, specific cell populations expressing L1CAM alone or in combination with the established CSC marker CD133 were isolated from three ovarian cancer cell lines. Double-positive L1CAM+/CD133+ cells displayed higher spherogenic and clonogenic properties in comparison to L1CAM−/CD133− cells. Furthermore, L1CAM+/CD133+ cells retained highest clonogenic capacity after irradiation and exhibited up-regulation of some CSC-specific genes, enhanced tumor-initiating capacity, self-renewal and higher tumor take rate in nude mice when compared with other cell populations. Superior radioresistance by L1CAM expression was confirmed by deletion of L1CAM using CRISPR-Cas9 technology. Moreover, we found expression signatures associated with epithelial-to-mesenchymal transition phenotype in L1CAM deleted cells. These results indicate that L1CAM in combination with CD133 defines a new cancer cell population of ovarian tumor-initiating cells with the implication of targeting L1CAM as a novel therapeutic approach for ovarian CSCs., Cancers, 12 (1), ISSN:2072-6694
- Published
- 2020